Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?
Genmab and AbbVie said the Phase 3 EPCORE DLBCL-1 trial of epcoritamab failed its U.S. overall survival primary endpoint, though the drug keeps accelerated FDA approval. Genmab reported H1 2026 revenue of $2.051B and raised 2026 guidance to $4.325–$4.525B. AbbVie reported Q2 2026 net revenues of $16.99B and EPS $3.65.
How this was made
The 30-second read
Why it matters
The key new trading-relevant element is the US endpoint clarification: overall survival was not statistically significant, so the companies must rework the regulatory strategy with the FDA despite accelerated approval status.
Market read
Traders should weigh regulatory-path uncertainty for epcoritamab against AbbVie’s diversified earnings base, with Genmab facing the sharper risk skew.
What to watch
The article does not quantify epcoritamab’s current commercial traction or the specific regulator feedback timeline, which could dominate near-term price action more than the headline endpoint miss.
Background
The EPCORE DLBCL-1 Phase 3 study compared epcoritamab monotherapy versus investigator’s choice chemoimmunotherapy in transplant-ineligible relapsed/refractory DLBCL; the US primary endpoint was overall survival.
Ticker impact
AbbVie is a co-developer of epcoritamab, and the US Phase 3 EPCORE DLBCL-1 trial missed its overall survival endpoint, forcing regulator discussions.
Choppy, headline-driven moves possible around FDA/regulatory updates, but less likely to drive a sustained repricing versus Genmab.
The article frames the setback as absorbed by AbbVie’s immunology engine, with the key incremental variable being FDA feedback on epcoritamab’s path forward.
Genmab’s epcoritamab Phase 3 EPCORE DLBCL-1 failed to show statistically significant overall survival benefit in the US, despite maintaining accelerated FDA approval.
Higher probability of downside volatility until regulators and the companies clarify the post-failure data review and potential path forward.
The article explicitly states the trial missed the sole US primary endpoint (overall survival), creating direct uncertainty for regulatory outcomes tied to the asset’s commercial and approval trajectory.
Market effects
Reinforces heightened scrutiny for oncology bispecifics on confirmatory trials, potentially pressuring sentiment across similar late-stage programs.
US-focused regulatory endpoint failure can weigh on US-listed biotech sentiment, even if accelerated approvals remain in place.
Could influence global investor risk appetite for T-cell engaging bispecifics and confirmatory-trial read-throughs.
Counterpoint
Accelerated FDA approval remains intact, so the market may be over-discounting the confirmatory failure until regulators specify an acceptable evidence path.
Key entities
- drug_programepcoritamab (DuoBody-CD3xCD20)
T-cell engaging bispecific antibody co-developed by Genmab and AbbVie.
- clinical_trialEPCORE DLBCL-1 Phase 3
US primary endpoint was overall survival; the trial failed to meet statistical significance.
- regulatory_statusFDA accelerated approval status
The article says accelerated approval remains, but conversion to full approval is now more uncertain.
